MENINGOCOCCAL GROUP B VACCINE

Protect your adolescent and adult patients from serogroup B meningococcal disease

We are very pleased to announce the addition of our newest vaccine vendor partner – PFIZER. CASA members may now choose to participate in the Pfizer program to receive CASA member discounts on Trumenba® (Meningococcal Group B Vaccine) that is now available for use in the United States.

Trumenba is a new FDA-approved vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.

Trumenba is approved based upon demonstrated immune response against four group B strains representative of prevalent strains in the United States. The effectiveness of Turmenba against diverse group B strains has not been confirmed. Now, with Trumenba, you can help protect your adolescent and you adult patients from serogroup B meningococcal disease. Trumenba is now available.

How to participate in the Pfizer program for Trumenba

2. Check the Pfizer box at the top of the agreement (top left section of the agreement)
3. Please supply your DEA Number and Pfizer Account Number on the agreement
4. If you need a Pfizer Acct. # please call 800.666.7248 or visit www.pfizerprime.com
5.Sign, Date and return to CASA via fax at 866.243.9904 or email

We will contact you when you become eligible. To view the latest information about Trumenba as well as full Prescribing information, please visit www.TRUMENBAhcp.com.